Drug intelligence / Profile preview

ketum

Development stage
Phase 1
Lead developer
Universiti Sains Malaysia
Modality
Small Molecules
Administration
Oral
01

Overview

Ketum (*Mitragyna speciosa*) is a tropical evergreen tree indigenous to Southeast Asia, traditionally used for its stimulant and opioid-like analgesic properties. The plant contains several active alkaloids, most notably mitragynine and 7-hydroxymitragynine, which act as partial agonists at the mu-opioid receptor. Universiti Sains Malaysia (USM) has been actively researching the plant's therapeutic potential, specifically investigating its analgesic effects and impact on pain tolerance. In clinical trial settings, USM has evaluated ketum decoctions in chronic users using the cold pressor task to determine its efficacy in increasing pain threshold and tolerance compared to placebo. While it exhibits potential as an alternative for pain management, it remains a subject of significant regulatory and safety scrutiny due to its potential for dependence and its complex pharmacology involving multiple neurotransmitter systems.

Other names
kratomMitragyna speciosabiak-biak
02

Targets

ADRA2A (α2A)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ketum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketum.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call